The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology.

Engineering 52

Engineering Protein Expression Research Laboratories RNA 52

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.

RNA 246

RNA Engineering Therapies Disease 246

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

DECEMBER 8, 2020

The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Laying down a new track for RNA processing, Remix launched with $81 million in financing.

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 10, 2021

ILP100 is a genetically engineered Lactobacillus that acts as a small bioreactor on site in the wound, continuously introducing a chemokine, CXCL12, into the wound tissue. The drug is an RNA interference (RNAi) therapeutic. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.

Clinical Trials 52

Clinical Trials Trials FDA Protein Expression 52

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142